Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link

Tilman E Klassert, Shyam A Patel, Pranela Rameshwar

Department of Medicine – Division of Hematology/Oncology, New Jersey Medical School, Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA; Instituto de Enfermedades Tropicales y Salud Pública, University of La Laguna, Canary Islands, Spain

Correspondence: Pranela Rameshwar
UMDNJ-New Jersey Medical School, MSB, Rm. E-579, 185 South Orange Ave, Newark, NJ 07103, USA
Tel +1 973 972 0625
Fax +1 973 972 8854
Email rameshwa@umdnj.edu

Abstract: After many decades of neuropeptide research, advances in the field of tachykinins have considerably increased and revealed their implications in several physiological processes. In this review we focus on the role of the tachykinins in the regulation of hematopoietic functions. Evidence has shown that neural control of this process is emerging as a significant category in hematopoietic modulation. In the context of this regulation, we discuss the existence of a complex network involving the neurokinin receptors, tachykinins and cytokines. This network is tightly regulated by each of its components.

Keywords: hematopoiesis, tachykinins, neurokinin receptor, crosstalk, regulation

Introduction

The adult immune system arises from a definitive number of hematopoietic stem cells in the bone marrow (BM). This process, termed hematopoiesis, is orchestrated through a complex series of events, in which soluble factors play a critical role. These soluble factors include cytokines, chemokines, neurohormones and neuropeptides. These mediators have been shown to be involved in the interactions between the brain, BM, and immune system, and known as the neural–hematopoietic–immune axis. Neural control of hematopoiesis is emerging as a central category in hematopoietic regulation. Bidirectional crosstalk between the neurological mediators and hematopoiesis has been demonstrated by various studies and has been shown to serve as a regulatory mechanism. This crosstalk mainly occurs by the release of neuropeptides termed tachykinins from innervated fibers. These neuropeptides interact with specific receptors on BM resident cells and release other hematopoietic regulators such as cytokines, forming a complex network that regulates hematopoiesis. This review focuses on the role of tachykinins and their receptors in hematopoiesis and discusses how their crosstalk and regulation allows for maintenance of homeostasis in the BM.

Tachykinins

Tachykinins comprise of a family of structurally related and evolutionary conserved peptides characterized by the common carboxy-terminal sequence FXGLM-NH₂. Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB) are the best known members of this family. Von Euler and Gaddum identified the first tachykinin, SP, in 1931. Forty years later, it was chemically characterized by Chang and Leeman. In the mid-1980s, NKA and NKB were identified by multiple groups, and since then, tachykinins have been extensively studied for their roles in many pathological and physiological processes, including hematopoiesis.
The three known genes that encode mammalian tachykinins are TAC1, TAC3, and TAC4, also termed as preprotachykinin A (PPT-A), -B (PPT-B), and -C (PPT-C), respectively.\(^7\) TAC1 encodes SP, NKA, and the extended forms of NKA (NPK and NP\(\gamma\)). TAC3 encodes for NKB, and the recently discovered TAC4 gene encodes for the new tachykinin members, hemokinin-1 (HK-1), its N-terminally extended forms endokinin A (EKA), endokinin B (EKB), and the tachykinin-related peptides endokinin C (EKC), and endokinin D (EKD).\(^7,14\) Biosynthesis of the tachykinins includes posttranscriptional processing of these genes, leading to their different splice variants.\(^15\) Translation of these mRNAs and posttranslational processing ends with a peptide \(\alpha\)-amidation and gives rise to the different tachykinins.\(^16,17\) The ultimate sequence is a dec- or decapeptide for most of the tachykinins.\(^15–17\) Other smaller forms of each member of the tachykinin family can be generated by enzymatic degradation of endogenous enzymes. As an example, a 4-amino acid peptide (SP [1–4]) can be generated by digestion of SP with human BM-derived endopeptidase.\(^18\) This small peptide showed negative effects on hematopoietic regulation, which contrasted the stimulatory effect SP.\(^5,18\) This underscores the complex functions of tachykinins, which could occur in multiple tissues and organs.

Tachykinins are widely distributed within both the central and the peripheral nervous system.\(^7\) Despite the initial consideration of tachykinins as neuropeptides, tachykinins have been shown to be not merely restricted to nerves, as its expression has been identified in non-neural tissues including cells of the BM and mature blood cells.\(^7,19,20\) In fact, the recently discovered third tachykinin gene TAC4 is predominantly expressed in nonneural tissues.\(^20\) The tachykinins can be considered as soluble links between the nervous system and other organs. As an example, the tachykinins have been shown to mediate a link within the neural–immune–hematopoietic axis.\(^5,21\)

The wide distribution of the tachykinins has implicated this family of peptides with several other physiological and pathological processes. However, this review will focus on the tachykinins as hematopoietic modulators. Functional homeostasis by members of the tachykinins include processes of reproduction, blood pressure and nociception.\(^15,22\) The major tachykinin, SP, has been associated to varied pathological processes, such as its facilitating role in HIV-1 infection and hematological and nonhematological malignancies.\(^15,23,24\) Due to the presence of the tachykinins in the neural system, it is not a surprise that this family of peptides would be linked to neurological conditions, such as depression, anxiety, Parkinson’s disease and Alzheimer’s diseases.\(^25–27\) The tachykinins have also been implicated in traumatic brain injury, ischemic encephalopathy and epileptic seizures.\(^28–30\) Most of the biological actions of tachykinins are exerted by their binding to the NK receptors.\(^15\)

**Neurokinin receptors**

Neurokinin receptors belong to family 1 (rhodopsin-like) of G protein-coupled receptors (GPCRs), which play a key role in cell signaling.\(^31,32\) GPCRs are characterized by sharing the same structural motif, including seven hydrophobic transmembrane domains with three extracellular loops and three intracellular loops.\(^32–34\) GPCRs are able to recognize a variety of ligands and stimuli from the extracellular environment and transmit information to the interior of the cell by interacting with the G-proteins. By activation of second messengers, GPCRs regulate a highly interconnected network of chemical pathways.\(^35\) The importance of these receptors becomes apparent since half of the commercially available drugs target the superfamily of GPCRs.\(^33\)

Currently, three different NK receptors have been identified, named NK1, NK2 and NK3. Although naturally occurring tachykinins can act as full agonists on any of the NK receptors, SP and HK-1 exhibit preferential binding to the NK1 receptor, whereas NKA and NKB show more affinity to NK2 and NK3 receptors, respectively.\(^15,34\) Three different genes termed TAC1R, TAC2R, and TAC3R encode for the NK1, NK2, and NK3 receptors, respectively.\(^31,34\) These evolutionary conserved genes contain five exons interrupted by introns. Interestingly, the feature to retain introns is rather uncommon in the superfamily of GPCRs. Nevertheless, this characteristic of the neurokinin receptors permits the generation of functionally different splice variants, which have been observed for both NK1 and NK2 receptors.\(^15\) For example, two different TAC1R isoforms have been described differing in the length of their C-terminal tails, and thus in their functional properties.\(^36,37\) Recent studies have related the expression of these isoforms to innate immunity and HIV neuropathogenesis.\(^38,39\)

The tachykinin NK1 receptor is ubiquitously expressed in mammals and has been found in neurons, vascular endothelium, muscle, different immune cells, and BM, among others.\(^7,19,35\) The tachykinin NK2 receptor is mostly expressed in peripheral tissues with restricted expression in the central nervous system (CNS).\(^34\) Finally, the tachykinin NK3 receptor is preferentially expressed in the CNS.\(^34\) Regarding hematopoietic cells, NK1 and NK2 expression
has been established in mature immune cells, hematopoietic progenitors, mesenchymal stem cells (MSCs) and BM stroma.13,19

Reports of tachykinin-mediated processes which seem to be NK receptor-independent,40 and the recent identification of novel tachykinins22 have reopened the question about the existence of a fourth NK receptor. While attempts to find additional NK receptors have been unsuccessful, the question remains a focal point due to the identification of tachykinins that appear to interact with receptors other than those of the NK family; and crosstalk between NK receptor subtypes in human models of hematopoiesis.41

The intracellular signaling pathways following NK1 and NK2 activation are complex, similar to all GPCRs. Among the possible intracellular signaling pathways activated by GPCRs, NK1 and NK2 activation has been shown to evoke both calcium (Ca\(^{2+}\)) and cyclic adenosine monophosphate (cAMP) responses.52-44 The primary G-protein responsible for Ca\(^{2+}\) triggering pathways is Goq, whereas G\(\alpha\)s activates adenylyl cyclases.44 NK receptors can also bind G\(\alpha\)i, which inhibits the adenylyl cyclases.35 Downstream mediators of the different NK-induced pathways include protein kinases A (PKA) and C (PKC), Ras, Raf-1, MAP/ERK kinase (MEK), extracellular signal-regulated kinase (ERK) and NF\(\kappa\)B.45,46 Recently, a new NK1 receptor signaling cascade via phosphoinositide-3 kinase (PI3K)-Akt has been demonstrated in studies with mouse dendritic cells.47 Similar activation has been reported for human non-tumorigenic breast cells.48 Nevertheless, classic NK1 receptor signaling mostly involves phospholipase C (PLC) as a second messenger producing inositol triphosphate (IP3) and diacylglycerol (DAG), with the downstream release of Ca\(^{2+}\) and PKC activation. These findings suggest that Goq is the dominant G-protein subunit in NK1 activation.40 Ca\(^{2+}\) response also seems to be the preferential pathway in NKA/NK2-receptor activation.46 However, it should be noted that these studies were performed in cell lines, which are by definition, cells with a degree of transformation. These findings will need to be taken speculatively in studying primary cells, which might show tissue specificity. The intracellular signal transduction pathways of NK receptor signaling could be subjected to termination by a variety of GPCR kinases (GRKs) and second messenger-regulated kinases.40 This could occur by the phosphorylation of the NK receptors and recruitment of the cytosolic scaffolding proteins arrestins to prevent additional interactions.40 The recruitment of the arrestins could be linked to receptor recycling, although the method of recycling might be cell-specific.51,52

The ability of NK receptors to activate different effector systems has been explained, at least in part, by the finding that GPCRs exist in equilibrium between different active conformations.13,33 In this multistate model of GPCR activation, both the extracellular microenvironment and also the ligand seem to condition the conformation adopted by the receptor and thus the activation of one or more pathways.15 This has been demonstrated for the NK1 receptor, after observing its different binding affinities to either SP or the nonnatural ligands NKA and Septide.33 Similar evidence has been shown for the NK2 receptor, where the truncated form of NKA (NKA-(4-10)) evokes only a Ca\(^{2+}\) response whereas the binding of naturally occurring, full-length, NKA caused the accumulation of cAMP.44 Despite the experimental studies with ligands, the limiting factor for functions could be the receptor. This is demonstrated by in vitro studies on hematopoiesis with human bone marrow cells. Stimulation with the tachykinins and in the presence, or absence of, receptor antagonists indicated that the receptor, and not the ligand limits the function of the particular ligand.35,65,56 If SP interacts with NK1 by in vitro studies, the outcome recapitulates hematopoietic stimulation.55 Similar stimulation with NKA through NK2 resulted in the opposite outcome.56

### Hematopoiesis

Hematopoiesis is the process by which blood and immune cells are generated from hematopoietic stem cells (HSCs) by differentiation along multiple lineages.57,58 HSCs can self-renew and can show long-term repopulation of an animal’s immune system. The HSCs are located in low O\(_2\) regions of the BM, close to the endosteum.59 Long-term reconstituting HSCs can give rise to short-term repopulating cells, which then yield common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs), with each being able to differentiate along multiple lineages to produce both immune and blood cells.60 CLP gives rise to B cells, T cells, and natural killer cells whereas CMP produces erythrocytes, megakaryocytes, monocytes, basophils, neutrophils and eosinophils.13,58 The process of hematopoiesis is tightly regulated at several levels by a complex network of soluble factors, including cytokines and neuropeptides.13

The regulation of hematopoiesis involves functional support of HSCs by the BM niche.1,61 This niche could stimulate hematopoiesis as well as exert negative feedback to maintain homeostasis in BM. As an example, MSCs, can negatively regulate hematopoiesis via the generation of adipocytes.61,62 This role of MSCs is important when one considers that MSCs are located around the main blood...
vessels of the marrow cavity where they are bypassed by cells entering and exiting the marrow. Another important role for MSCs is their ability to differentiate into two of the hematopoietic-supporting cells, stroma and osteoblasts. These hematopoietic-supporting cells are located near the endosteal area of the bone in a relatively hypoxic microenvironment. Although *in vitro* studies have demonstrated a significant role of NK receptors and the tachykinins in the functions of stroma in hematopoietic regulation, further studies are required with *in vivo* models. These studies are particularly important because stromal cell interactions with HSCs are relevant to the functions of HSCs, such as migration and progenitor expansion versus hematopoietic reconstitution. It appears that there is heterogeneity among stromal cells in the BM and this is relevant to stromal interaction with the HSCs. This finding is significant because it lends itself to future studies geared towards determining if subsets of stroma show varied expressions of NK receptors.

Hematopoiesis is regulated by soluble regulators such as cytokines, chemokines, and growth factors. Cytokines are the prototypical regulators of hematopoiesis. The hormone erythropoietin is also important to hematopoietic regulation, in particular in the erythroid phase. Significant cytokines that are linked to the tachykinins include stimulatory interleukins (ILs) such as IL-1, IL-3, IL-6, IL-11 or the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), and inhibitory factors such as macrophage inflammatory protein-1α (MIP-1α) and transforming growth factor-β (TGF-β), among others. Similarly, SP is linked to the receptor/ligand interaction between stem cell factor (SCF) and c-kit, which has trophic effects on hematopoiesis. Cytokines are not only relevant to specific sites of hematopoiesis, but they are important across the cavity, where various maturational stages of hematopoietic progenitors can be located. Gradient changes of growth factors are significant to the outcome of hematopoiesis. Among the functions of cytokines is the role of matrix metalloprotease activity that regulates the decision of HSCs to retain cell cycle quiescence or to exit the cycling state. The discussion in this section is not only relevant to hematopoietic homeostasis, but to hematopoietic failure pathologies, such as leukemias and myeloproliferative disorders. Appreciation of the relevance of cytokines and other factors requires studies on the tachykinins and neurokinins to enhance and understand BM functions.

The literature on BM innervation by the sympathetic and peptidergic fibers has led to deeper insights into the neural role of hematopoietic regulation. Since evidence has shown that neuropeptides, neurotransmitters, neurotrophic factors and neurohormones are involved in hematopoiesis, neural control of this process is emerging as another category in hematopoietic regulation. Moreover, it has been shown that peptides of neural origin establish a network with classical regulators of hematopoiesis. This network connects the BM, brain, and the immunological system, and these regulators demonstrate intercellular crosstalk.

### Tachykinins in the neural–hematopoietic–immune axis

The links among the brain, BM and immune system were established by anatomical studies. An understanding of these interorgan links is important to appreciate how the tachykinins could be involved in the loss of homeostasis, which could be due to BM-derived dysfunction or the movement of malignant cells in the BM. This section will link the varied dissected information on the tachykinins to hematopoiesis and immune functions (Figure 1). The BM receives innervations by substance P-secreting neurons, as well as other neurotransmitters. The nervous system may serve as the source of upsurge in hematopoiesis, which is then fine-tuned by cytokine signaling.

A well-studied receptor/ligand interaction that is involved in the functions of HSCs is the chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12), and its receptor, CXCR4. CXCL12 also regulates inflammation, and disruption studies of CXCL12-CXCR4 by the antagonist AMD3100 have demonstrated that this ligand-receptor pair is important in the mobilization of HSCs from BM to the periphery. SDF-1 also contributes to cell migration, cell survival and angiogenesis. An increase in CXCL12 could lead to hematological malignancies, as well as the metastasis of cancer cells to BM. If CXCL12 is relevant to BM functions, the question is how its biology can be facilitated by the tachykinins.

In *vitro* studies with cells from human BM aspirates strongly suggest that the neural-hematopoietic-immune axis could involve a crosstalk between CXCL12 and TAC1 peptides. Functions of CXCL12 on BM homeostasis are not limited to hematopoietic regulation, they are also involved in the pathology of BM. The role of CXCL12 appears to be secondary to the induction of TAC1, and this could lead to the entry of human breast cancer cells into BM. Both breast cancer cells and hematopoietic cells demonstrate constitutive expression of TAC1. The roles for TAC1 in angiogenesis, metastasis and survival of cancer cells are significant for entry of human cancer cells to BM. While CXCL12 is discussed
in this section, expression of other cytokines may also be secondary to the expression of TAC1 and NK receptors. The oncogenic properties of TAC1 involve the loss of the tumor suppressor gene REST.

In addition to CXCL12, SP can mediate an increase in the production of granulocyte-macrophage colony stimulating factor (GM-CSF) in human BM mononuclear cells. This growth factor could be important in the mobilization of HSCs, and might act in concert with CXCL12. In summary, this section describes a role for TAC1 in BM functions during homeostasis, mobilization of HSCs and metastasis of breast cancer into BM; underscoring the emerging role of the tachykinins in BM functions.

**Tachykinins and neurokinin receptors in hematopoiesis**

Experimental studies with human BM aspirates from healthy subjects and patients with myeloproliferative disorders, with or without fibrosis, showed relevance for NK1 and NK2 in BM homeostasis and during dysfunctions. The most reported tachykinins involved in hematopoiesis are SP and NKA. These TAC1 peptides can be present in BM through two sources: release by the innervating nerve fibers; and the production in resident human BM cells such as endogenous stromal cells. HK-1, a tachykinin from TAC4, has also been implicated in B- and T-cell human lymphopoiesis, again, by in vitro methods.

SP and NKA have been shown to regulate hematopoiesis at various stages of the hematopoietic hierarchy. These studies have been demonstrated with human and murine BM cells. Studies with a murine model on the lymphoid
lineage have demonstrated a role for SP in B-cell maturation. In the erythro-myeloid lineage, SP mediates stimulatory effects on their progenitors. Contrary to SP, NKA exerts diverse effects on erythroid progenitors and inhibits proliferation of granulocytic-monocytic progenitors.

Together, these findings indicate that the TAC1 gene can regulate hematopoiesis not only through stimulatory effects, but also through its own negative feedback. This conclusion is supported by studies with human cells that correlate with the production of relevant cytokines.

However, the significance of these studies require more in-depth analysis with molecular approaches as well as in vivo models with knockout and transgenic mice.

To date, the experimental studies on the role of the hematopoietic microenvironment indicate that BM stroma could be a critical cellular link in the crosstalk between the tachykinins and hematopoiesis (Figure 2A). In vitro studies with stroma from human BM aspirates have shown that each tachykinin induces the production of specific cytokines. SP interacts with NK1 on the human stromal cells or human BM mononuclear cells to induce the production of stimulatory mediators such as IL-1, IL-2, IL-3, IL-6, TNF-α, SCF and GM-CSF. The proliferative effects observed by SP-NK1 coupling on hematopoietic cells are therefore partly explained by indirect production of cytokines and growth factors involved, among other processes, in cell-cycle transition.

On the other hand, NKA may be relevant to cell cycle control via checkpoint regulation, potentially conferring protective effects on HSCs. NKA induces the release, by stromal cells, of the inhibitory cytokines MIP-1α and TGF-β. Recently, a direct NK2-mediated regulation mechanism has also been described, by which NKA inhibits cell-cycle transition in the human hematopoietic progenitor cell line K562. Although NK2 is expected to activate G-protein-linked pathways, the effect of NKA on K562 occurs through Smad proteins. This finding is highly suggestive that there could be intracellular crosstalk between NK2 and other activators. The interaction between NKA and NK2 leads to the activation of the cell cycle inhibitors, p53, p21 and Smad4, while suppressing the cell cycle activators Cdk2 and CyclinA.

Neurokinin receptor crosstalk in hematopoietic functions

The effects of NK1 and NK2 on hematopoiesis are divergent. NK1 mediates the production of cytokines linked to hematopoietic stimulation, whereas NK2 activation induces inhibitory mediators. Therefore, it seems logical that the expression of either NK1 or NK2 could determine the outcome of hematopoietic functions. Indeed, co-expression of both receptors is not observed in most human BM resident cells, in particular the stromal cells. Moreover, the induction of one NK subtype correlates with a decrease of the other subtype, showing a “yin-yang” type of expression, at least in human stromal cells. This is relevant to hematopoietic functions since the stromal cells are critical in the support of hematopoiesis.

Neurokinin receptors have been shown to be able to regulate their own expression (Figure 2B). SP-NK1 interaction can induce TAC1R transcription, a process mediated by the activation and translocation to the nucleus of NFκB. Cytokines induced by NK1 activation, such as IL-1, IL-3, IL-6 and GM-CSF, can constitute an indirect stimulation method of NK1 receptor production. The regulatory region of NK1 indicated that binding sites for NFκB and cAMP response element (CRE) are important in controlling the responses to cytokines in the induction of NK1. Recently, auto-regulation of the NK2 receptor was also noted. In both primary BM cells and progenitor cells, NK2 receptor activation by NKA leads to increased expression of its own mRNA. In this case, TAC2R transcription seems to be mediated by p53 activation and its binding to the gene promoter. The induction of the NK2 receptor by NKA is also regulated by autocrine production of TGF-β in stroma.

The complex biology of the NK receptors is compounded by evidence of intracellular crosstalk between the subtypes within primary human BM stroma. Use of a specific NK2 receptor antagonist in an in vitro model of human hematopoiesis, resulted in enhanced hematopoietic response by SP. These studies indicated that in the absence of NK2, the balance in hematopoietic function by NK1 is altered. The enhancement of hematopoietic activity correlated with NK1 receptor upregulation at both protein and mRNA levels. On the other hand, blunting of the NK1 receptor resulted in the reduction of cell proliferation, and upregulation of the NK2 receptor at both protein and mRNA levels. These results indicated the existence of intracellular crosstalk between NK1 and NK2 and this crosstalk is highly relevant to hematopoietic balance. The molecular mechanisms underlying intracellular crosstalk between NK1 and NK2 are under investigation and might hold the key to several disorders linked to diseases.

GPCR signaling generally involves the activation of different secondary messengers, such as PKC and PKA that can mediate receptor crosstalk. This could occur by converging and/or counteracting signaling pathways.
following receptor activation.\textsuperscript{108,109} As discussed above, several intracellular pathways can be activated by GPCRs. The activation of NK1 and NK2 mostly involve pathways that include Ca\textsuperscript{2+} and PKC.\textsuperscript{42,44} The activation of PKC leads to the downstream activation of ERK1/2 and NF\kappa B.\textsuperscript{109} In other studies, NK1 stimulation led to the activation of the PI3K-Akt pathway in dendritic cells.\textsuperscript{47} This brings up a question of cell-specific signaling pathways in the activation of NK1 versus newly identified mechanisms from NK receptor activation. Similar pathways in activated macrophages suggest that the PI3K-Akt signaling pathway might be relevant to antigen presenting cells.\textsuperscript{108} Furthermore, the importance the PI3K-Akt signaling pathway has been shown in NK1-mediated inflammatory responses, in macrophages, interacting with the PKC-ERK1/2-NF\kappa B signaling pathway.\textsuperscript{109}

Beside NF\kappa B, transcription factors binding CRE have also been shown to be implicated in NK1 regulation. These are downstream of the cAMP pathway, which is also linked to NK1 and NK2 activation.\textsuperscript{42,44,105} It has been suggested that this pathway could also inhibit NK1 expression through the inducible cAMP early repressor (ICER).\textsuperscript{105,110} While it is important to map intracellular pathways that are activated by the NK receptors and to understand how these receptors are regulated, further insights will be gained by studies to decipher how these pathways interact with each other to regulate the biology of the NK subtypes within a milieu of factors such as inflammatory mediators.

Crosstalk between NK receptor subtypes can be partly explained by indirect cytokine-mediated regulation.\textsuperscript{5,82} We have already exposed how each receptor is able to induce its own expression by specific cytokines and transcription factors. Similarly, a particular NK receptor subtype can induce a specific cytokine to inhibit the expression of the other receptor subtype.\textsuperscript{41,103} These regulatory networks are important to functions. As an example, it has been demonstrated that SP and GM-CSF were able to negatively control the NKA-NK2-p53 induced stimulation of NK2 expression, with concomitant downregulation of p53 in a

---

**Figure 2**: Illustration summarizes the involvement of NK receptors on hematopoietic regulation and the outcome of crosstalk between NK1 and NK2. **Notes:** Left: shows the NK1-mediated stimulation; Right: NK2-mediated hematopoietic inhibition. Substance P (SP) interaction with NK1 leads to stroma-mediated production of stimulatory cytokines, and neurokinin-A (NKA) stimulation resulted in the release of inhibitory cytokines (A). Crosstalk between these receptors is partly explained by the expressions of NK1 and/or NK2, respectively. Expression of each gene is tightly regulated by SP, NKA and their induced cytokines (B). NK1 or NK2 expression causes hematopoietic stimulation or inhibition, respectively (C). The production of a particular TAC1 peptide depends on the ligand, SCF by SP and TGF-β by NKA (D). Black arrows depict upregulation; Red lines depict downregulation.
human hematopoietic progenitor cell line. On the other hand, TGF-β, an NK2-induced cytokine, can decrease the expression of NK1 in primary human BM stroma. Figure 2 shows the intricate interplay between tachykinins, cytokines and growth factors that leads to the expression of either NK1 or NK2 receptors, and thus, to either a stimulatory or an inhibitory effect on hematopoiesis. This interplay begins or terminates, depending on the context of the biological process, at the level of gene expression.

The regulation and crosstalk among the NK receptors is not limited to intracellular interactions, it also involves physical interactions at the cell membrane. A discussion of how this occurs by other GPCRs could be extrapolated to NK receptor subtypes. For example, heterodimerization of the prostaglandin E₂ type-1 receptor (EP1R) and the β₂-adrenergic receptor (β₂AR) in airway smooth muscle cells can lead to uncoupling between β₂AR and its G-protein to reduce the outcome of the natural ligand. Further studies may explain whether GPCR dimerization plays a role in NK1 and NK2 intracellular crosstalk.

TAC1 peptides, SP and NKA, are the natural ligands which activate both the NK1 and the NK2 receptor. Thus, besides the regulation of the TAC1R and TAC2R genes, TAC1 expression will also be a deciding factor in keeping the balance between NK1 and NK2 receptor mediated actions. At this level, CXCL12 has been shown to regulate TAC1 expression and this effect is concentration-dependent, indicating that this chemokine exerts a fine control of TAC1 expression. The RE-1 silencer of transcription (REST) synergizes with miRNAs and RNA-binding proteins regulation by miRNAs and RNA-binding proteins (RBPs) has been recently proposed in stromal cells.

However, this review discusses the existence of a complex network involving the neurokinin receptors, their ligands and cytokines. These parameters in this network are subjected to tight regulation, partly by receptor crosstalk at several levels. These NK receptor interactions may comprise: cytokine-mediated pathways; intracellular signaling; and molecular crosstalk. Regulation of this network has not only diverse physiological implications in the BM, but also pathological implications. Disruption of BM homeostasis has been linked to hematological disorders, such as BM fibrosis and leukemia. The current state of evidence warrants further research in this field.

Acknowledgment

This work was supported by the FM Kirby Foundation and the FPU grant AP2005-4921 to Tilman E. Klassert.

Disclosures

The authors report no conflicts of interest relevant to this research.

References


57. Simmons PJ, Levesque JP, Zannettino AC. Adhesion molecules in

56. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators

69. Meunch MD, Schneider JG, Moore MAS. Interaction amongst

65. Corcoran KE, Trzaska KA, Fernandes H, et al. Mesenchymal stem cells

61. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ.


62. Sugimura R, Li L. Shifting in balance between osteogenesis and

72. Lapidot T, Dar A, Kollet O. How do stem cells find their way home?

coupled receptor kinase interaction with the neurokinin-1 receptor


50. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination

71. North TE, de Brujin MF, Stacy T, et al. Runx1 expression marks

73. Corcoran KE, Patel N, Rameshwar P. Stromal derived growth

75. Zhang Y, Pai GI. T-cell developmental blockage by tachykinins


88. Rameshwar P, Joshi DD, Yadav P, et al. Mimicry between neurokinin-1


60. Martinez-Agosto JA, Mikkola HK, Hartenstein V, Banerjee U. The


61. Bennett VI, Perrine SA, Simmons MA. Neurokinin-1 receptor resensitization


51. Bennett VI, Perrine SA, Simmons MA. Neurokinin-1 receptor

58. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators

63. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting


64. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting

67. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem

54. Rameshwar P, Ganea D, Gascon P. In vitro stimulatory effect of

53. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ.

55. Rameshwar P, Ganea D, Gascon P. In vitro stimulatory effect of

74. North TE, de Brujin MF, Stacy T, et al. Runx1 expression marks

85. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4

68. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem

69. Meunch MD, Schneider JG, Moore MAS. Interaction amongst

78. Bischoff SC, Dahinden CA. Effect of nerve growth factor on the

86. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P. T\(\alpha\)c1

87. Tordjman R, Lepelletier Y, Lemarchand V, et al. A neuronal receptor,

56. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators

72. Lapidot T, Dar A, Kollet O. How do stem cells find their way home?

74. North TE, de Brujin MF, Stacy T, et al. Runx1 expression marks

64. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting

67. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem

53. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ.


51. Bennett VI, Perrine SA, Simmons MA. Neurokinin-1 receptor

58. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators

63. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting


65. Corcoran KE, Trzaska KA, Fernandes H, et al. Mesenchymal stem cells


